Live Analyst Rating Changes 10846 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/William Wood
BR
William Wood
B. Riley Securities
Wall Street Analyst
★★★☆☆
#1691
on 13Foresight · ranked by our own returns
50%
Success Rate
+6.2%
Average Return
7 of 14 calls profitable · -1.3% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 50% of William Wood's ratings turned a profit when each position was held for 1 year — averaging +6.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

16 Buy 0 Hold 0 Sell
William's Stock Coverage 14 ratings · 2026-07-21
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
TRVI
Trevi Therapeutics
 Jul 17, 2026 BUY Strong Buy
+29.4% avg upside
18 analysts
$31.00
76.80% Upside
 -12.1%
VKTX
Viking Therapeutics
 Jun 25, 2026 BUY Strong Buy
+96.7% avg upside
31 analysts
$85.00
128.57% Upside
 +1.8%
EQ
Equillium
 Jun 02, 2026 BUY Strong Buy
+279.8% avg upside
15 analysts
$6.00
140.92% Upside
 -10.4%
PALI
Palisade Bio
 Jun 02, 2026 BUY Strong Buy
+1310.8% avg upside
15 analysts
$7.00
257.97% Upside
 +5.4%
IMUX
Immunic
 May 22, 2026 BUY Strong Buy
+149.8% avg upside
21 analysts
$27.00
76.19% Upside
 +15.2%
AARD
Aardvark Therapeutics, Inc.
 May 15, 2026 BUY Buy
+216.3% avg upside
12 analysts
$7.00
17.62% Upside
 +38.5%
ALT
Altimmune
 Mar 06, 2026 BUY Strong Buy
+846.7% avg upside
20 analysts
$13.00
360.16% Upside
 -19.5%
MDGL
Madrigal Pharmaceuticals
 Dec 11, 2025 BUY Strong Buy
-11.5% avg upside
31 analysts
$670.00
24.98% Upside
 -4.7%
OKYO
OKYO Pharma Limited Sponsored ADR
 Dec 08, 2025 BUY Strong Buy
+445.5% avg upside
4 analysts
$5.00
261.09% Upside
 -27.8%
CGTX
Cognition Therapeutics
 Nov 21, 2025 BUY Strong Buy
+514.3% avg upside
9 analysts
$3.00
216.33% Upside
 -31.7%
VERU
Veru
 Feb 11, 2025 BUY Strong Buy
+750.0% avg upside
10 analysts
$50.00
2083.47% Upside
 -56.6%
LFMD
LifeMD
 Aug 08, 2024 BUY Strong Buy
+169.2% avg upside
14 analysts
$11.00
164.40% Upside
 +30.6%
CLPT
ClearPoint Neuro
 May 08, 2024 BUY Strong Buy
+54.1% avg upside
7 analysts
$10.00
33.39% Downside
 +137.9%
KRMD
REPRO-MED Systems
 May 02, 2024 BUY Strong Buy
+59.6% avg upside
9 analysts
$4.00
1.22% Downside
 +19.8%
🔒 9 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
William Wood — Frequently Asked Questions
How accurate are William Wood's stock ratings?
Based on the calls 13Foresight could measure, about 50% of William's ratings were profitable over a one-year hold, with an average return of +5.9% per rating, or -1.6% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is William ranked on 13Foresight?
William Wood is currently ranked #1691 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does William cover?
William most recently has ratings on TRVI, VKTX, EQ, PALI, IMUX, AARD, ALT, MDGL, OKYO, CGTX, VERU, LFMD and 2 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.